CHRS Q2 2025 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-84.2% YoY

Gross Profit

$7M66.9% margin

Operating Income

-$45M-443.6% margin

Net Income

$298M2903.9% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+34.9%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$439M

Total Liabilities

$320M

Stockholders' Equity

$120M

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$65M	-84.2%
Gross Profit	$7M	$35M	-80.6%
Operating Income	-$45M	-$21M	-121.8%
Net Income	$298M	-$13M	+2404.5%

Revenue Segments

Product and Service, Other

$295,000100%